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Abstract
Membrane fusion is a necessary process that allows
eukaryotic cells to carry and deliver cargo between organelles.
The mechanisms and machinery involved in membrane fusion
are conserved throughout eukaryotes, so the yeast vacuole
provides an ideal model system to study. Yeast vacuole fusion
proceeds through a series of stages that include priming,
tethering, docking, and fusion. Phosphatidic acid (PA) is a
glycerophospholipid present throughout eukaryotic organelle
membranes. The conversion of PA to diacyglerol (DAG) has
been shown to play an important role in the activity and
recruitment of vacuole fusion protein factors during the
priming and tethering stages. Increased PA levels at the
vacuole have been shown to significantly inhibit each of these
stages. In yeast, phospholipase D (Spo14) catalyzes the
hydrolysis of phosphatidylcholine into choline and PA making
it a protein of interest in our system. Spo14p activity has been
shown to play a vital role in numerous cellular pathways,
including signal transduction, membrane trafficking, and
regulation of mitosis. Here we aim to identify a role for Spo14
activity in the regulation of yeast vacuolar membrane fusion.
To date, we have demonstrated that deleting SPO14 causes a
marked increase in vacuole fusion that may be attributed to a
decrease in phosphatidic acid levels at the yeast vacuole.
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Future Directions
• Measure vacuole and whole cell phosphatidic acid 
content using thin-layer chromatography (TLC)
• Measure vacuole fusion of WT and spo14Δ using a 
standard inhibitor panel 
• Create spo14Δdgk1Δ and measure effects on 
membrane fusion and fusion factors
• Measure SNARE complex formation using GST-Vam7 
pulldown assay to compare WT and spo14Δ vacuoles
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• Spo14Δ shows a 50% increase in vacuole content 
mixing
• Sec18p priming is not altered in the spo14Δ
• Content of various membrane fusion associated 
proteins is not affected in the spo14Δ
• Indication that the spo14Δ has overall increased 
lipid mixing
Lipid Mixing
Figure 4: Sec18p priming is unaltered in spo14Δ. (A) Vacuoles from DKY6281 and 
spo14Δ yeast were assayed for priming activity as detected by the release of Sec17p from 
the vacuole membrane fraction. Fusion reactions of 3μg of vacuoles were used. Vacuoles 
were pelleted by centrifugation at the indicated time-points and proteins in the supernatant 
fraction were resolved by SDS–PAGE and imaged by western blot. (B) Percentage of Sec17p 
release was normalized and quantified to input values. 
Figure 3: Protein content at the 
vacuole unchanged in spo14Δ.
(A) Analysis of fusion components. 
Vacuoles were isolated from wild-
type BJ3505 and BJ3505 spo14Δ 
(5μg protein) and immunoblotted 
with antibodies against the 
indicated proteins. These fusion 
components include: SNAREs, 
SNARE chaperones, GTPases, 
and proteins associated with 
the homotypic fusion and protein 
sorting (HOPS) complex. (B) 
Analysis of overall vacuole protein 
content of BJ3505 and Spo14 
using Coomassie Blue staining.  
Vacuole Morphology and Spo14 Localization
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Figure 5: Spo14Δ shows an increase in fusion, but shows similar response to fusion inhibitors. (A) Fusion reactions were 
performed using wild-type and spo14Δ vacuoles. Reactions were incubated at 27C for the indicated times and assayed for Pho8 
activity. The green trace represents spo14Δ fusion when normalized to its own maximum. This reveals the rate of spo14Δ vacuole 
fusion vs wild type. (B) Fusion reactions were performed with treatment of anti-Ypt7 in a dose response manner. Increased levels of 
the Ypt7 inhibitor were used and relative fusion was measured at the end of the 90 minute reaction. Ypt7 is a GTP-binding protein of 
the Rab family and interacts with the HOPS complex to bring membranes close enough together for SNARE proteins to engage each
other and dock. (C) Fusion reactions were performed with treatment of guanosine nucleotide dissociation inhibitor (GDI). GDI binds 
to GDP-bound Rab GTPases and extracts them from the membrane.
Figure 6: Spo14Δ shows an 
increase rate of lipid mixing. (A) 
Lipid mixing assay were performed 
with wild-type and spo14Δ DKY6281 
vacuoles. Reporter vacuoles (2 μg) 
labeled with Rh-PE were incubated 
with 16 μg of unlabeled vacuoles. 
Fluorescence (λex= 544 nm; λem= 
590 nm) was measured every 60 
seconds for 80 minutes. (B) Raw lipid 
mixing data was quantified to show 
percent differences in rhodamine 
dequenching between strains.
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Figure 1: Vacuole morphology is consistent between wild-type DKY6281 and 
spo14Δ. Staining was done using a pulse-chase with the vacuole specific dye FM4-64. 
Wild-type and spo14Δ vacuole morphologies show no significant difference and no 
apparent fusion defect. There are specific regions in which the spo14Δ vacuoles show 
increased FM4-64 staining. 
Figure 2: GFP-tagged Spo14 localizes away from the vacuole. Spo14 is potentially 
shown to localize in smaller endosomal sites rather than the vacuole. 
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